Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis

被引:33
|
作者
Chen, Ying [1 ]
Huang, Lan [1 ]
Dong, Yongjian [1 ]
Tao, Changli [1 ]
Zhang, Rongxin [1 ]
Shao, Hongwei [1 ]
Shen, Han [1 ]
机构
[1] Guangdong Pharmaceut Univ, Sch Life Sci & Biopharmaceut, Guangdong Prov Key Lab Biotechnol Drug Candidates, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT1; E17K; mutation; cancer; prognisis; PLECKSTRIN HOMOLOGY DOMAIN; KINASE INHIBITOR P27(KIP1); SQUAMOUS-CELL CARCINOMA; E3; LIGASE; ONCOGENIC MUTATION; PIK3CA MUTATIONS; HUMAN BREAST; AKT1(E17K) MUTATIONS; ACTIVATING MUTATION; INSULIN-RECEPTOR;
D O I
10.3389/fcell.2020.573599
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The substitution of the seventeenth amino acid glutamate by lysine in the homologous structural domain of the Akt1 gene pleckstrin is a somatic cellular mutation found in breast, colorectal, and ovarian cancers, named p. Glu17Lys or E17K. In recent years, a growing number of studies have suggested that this mutation may play a unique role in the development of tumors. In this review article, we describe how AKT1(E17K) mutations stimulate downstream signals that cause cells to emerge transformed; we explore the differential regulation and function of E17K in different physiological and pathological settings; and we also describe the phenomenon that E17K impedes tumor growth by interfering with growth-promoting and chemotherapy-resistant AKT1(low)QCC generation, an intriguing finding that mutants may prolong tumor patient survival by activating feedback mechanisms and disrupting transcription. This review is intended to provide a better understanding of the role of AKT1(E17K) in cancer and to inform the development of AKT1(E17K)-based antitumor strategies.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] AKT1 (E17K) mutation in pancreatic cancer
    Mohamedali, Azim
    Lea, Nicholas C.
    Feakins, Roger M.
    Raj, Kavita
    Mufti, Ghulam J.
    Kocher, Hemant M.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2008, 7 (05) : 407 - 408
  • [2] E17K substitution in AKT1 in prostate cancer
    Boormans, J. L.
    Korsten, H.
    Ziel-van der Made, A. C. J.
    van Leenders, G. J. L. H.
    Verhagen, P. C. M. S.
    Trapman, J.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1491 - 1494
  • [3] SCREENING FOR AKT1 (E17K) MUTATION IN BREAST CARCINOMAS AND CONTROL SAMPLES
    Acosta, K. B.
    Gonzalez, M. C.
    Zapata, P. D.
    BIOCELL, 2014, 38 : 193 - 193
  • [4] E17K substitution in AKT1 in prostate cancer
    J L Boormans
    H Korsten
    A C J Ziel-van der Made
    G J L H van Leenders
    P C M S Verhagen
    J Trapman
    British Journal of Cancer, 2010, 102 : 1491 - 1494
  • [5] Ubiquitous expression of Akt1 p.(E17K) results in vascular defects and embryonic lethality in mice
    Lindhurst, Marjorie J.
    Li, Wenling
    Laughner, Nathaniel
    Shwetar, Jasmine J.
    Kondolf, Hannah C.
    Ma, Xuefei
    Mukouyama, Yoh-Suke
    Biesecker, Leslie G.
    HUMAN MOLECULAR GENETICS, 2020, 29 (20) : 3350 - 3360
  • [6] Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
    Mancini, Maria L.
    Lien, Evan C.
    Toker, Alex
    ONCOTARGET, 2016, 7 (14) : 17301 - 17313
  • [7] AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma
    Cohen, Yoram
    Shalmon, Bruria
    Korach, Jacob
    Barshack, Iris
    Fridman, Eddie
    Rechavi, Gideon
    GYNECOLOGIC ONCOLOGY, 2010, 116 (01) : 88 - 91
  • [8] Effects of AKT1 E17K mutation hotspots on the biological behavior of breast cancer cells
    Wu, Wanwen
    Chen, Ying
    Huang, Lan
    Li, Wenjian
    Tao, Changli
    Shen, Han
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2020, 13 (03): : 332 - 346
  • [9] Functional determination of AKT1(E17K) in human mammary epithelial cells
    Salhia, Bodour
    Carpten, John
    CANCER RESEARCH, 2009, 69
  • [10] The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias
    I S Mahmoud
    M A Sughayer
    H A Mohammad
    A A Eshtayeh
    A S Awidi
    M S EL-Khateeb
    S I Ismail
    British Journal of Cancer, 2008, 99 : 488 - 490